Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
D.W. Fraser, T.R. Tsai, W. Orenstein, W.E. Parkin, M.J. Beecham, R.G. Sharrar, et al.
Legionnnares’ disease: description of an epidemic pneumonia.
N Engl J Med, 297 (1977), pp. 1189-1197
[2.]
A.L. Benin, R.F. Benson, R.E. Besser.
Trends in Legionnarires disease, 1980-1998: declining mortality and new patterns of dianosis.
Clin Infect Dis, 35 (2002), pp. 1039-1046
[3.]
C.A. Joseph, T.G. Harrison, D. Ilijic-Car, C.L. Bartlett.
Legionnaries’disease in residents of Englans and Wales:1998.
Commun Dis Poublic Health, 2 (1999), pp. 280-284
[4.]
J.E. Stout, V.L. Yu.
Legionellosis.
N Engl J Med, 337 (1997), pp. 682-687
[5.]
A. Torres, J. Serra-Batlles, A. Ferrer, P. Jiménez, R. Celis, E. Cobo, et al.
Severe community-acquired pneumonia: epidemiology and proignostic factors.
Am Rev Respir Dis, 144 (1991), pp. 312-318
[6.]
R.M. Bláquez-Garrido, F.J. Espinosa-Parra, L. Alemany-Francés, R.M. Ramos-Guevara, J.M. Sánchez-Nieto, M. Segovia-Hernández, et al.
Antimicrobial chemotherapy for legionnaires disease: levofloxacin versus macrolides.
Clin Infect Dis, 40 (2005), pp. 800-806
[7.]
M. Falguera, O. Sacristán, A. Nogues, A. Ruiz-González, M. García, A. Manonelles, et al.
Non severe community-acquired pneumonia. Correlation between cause and severity or comorbidity.
Archiv Intern Med, 161 (2001), pp. 1866-1872
[8.]
N. Sopena, M. Sabria-Leal, M.L. Pedro-Botet, E. Padilla, J. Domínguez, J. Morera, et al.
Comparative study of the clinical presentation of Legionella pneumophila and other communtiy acquired pneumonias.
Chest, 113 (1998), pp. 1195-1200
[9.]
P.H. Edelstein.
Antimicrobial chemotherapy for Legionnaries’ disease: a review.
Clin Infect Dis, 21 (1995), pp. S265-S276
[10.]
A.L. Baltch, R.P. Smith, W.J. Ritz, M.A. Franke, P.B. Michelsen.
Antibacterial effect of thelithromycin and comparative antibiotics against intracellular Legionella pneumophila.
J Antimicrob Chemotherapy, 46 (2000), pp. 51-55
[11.]
P.H. Edelstein, W.J. Weiss, M.A.C. Edelstein.
Activities of tigecycline against Legionella pneumophila in vitro an din guinea pigs with L. pneumophila pneumonia.
Antimicrob Agents Chemother, 47 (2003), pp. 533-540
[12.]
Comparative in vitro activity and post-antibiotic effect of gemifloxacin against Legionella spp.
J Antimicrob Chemother, 45 (2000), pp. S41-S46
[13.]
P.H. Edelstein, T. Shinzato, M.A. Edelstein.
BMS-284756 (T-3811ME) a new fluoroquinolone: in vitro activity against Legionella, efficacy in a guinea pig model of L. pneumophila pneumonia and pharmacokinetics in guinea pigs.
J Antimicrob Chemother, 48 (2001), pp. 667-675
[14.]
P.H. Edelstein, T. Shinzato, E. Doyle, M.A. Edelstein.
In vitro activity of gemifloxacin (SB_265805, LB20304a) against Legionella pneumophila and its pharmacokinetics in Guinea pigs with L. pneumophila pneumonia.
Antimicrob Agents Chemother, 45 (2001), pp. 2204-2209
[15.]
V. Falcó, I. Molina, C. Juste, M. Crespo, B. Almirante, C. Pigrau, et al.
Tratamiento de la neumonía por Legionella pneumophila. ¿Macrólidos o quinolonas?.
Enferm Infecc Microbiol Clin, (2006), pp. 23
[16.]
M. Sabrià, M.L. Pedro-Botet, J. Gómez, J. Roig, B. Vilaseca, N. Sopena, et al.
Fluoroquinolones vs macrolides in the treatment of legionnaries disease.
Chest, 128 (2005), pp. 1401-1405
[17.]
A. Mykietiuk, J. Carratala, N. Fernandez-Sabe, J. Dorca, R. Verdaguer, F. Manresa, et al.
Clinical outcomes for hospitalized patients with Legionella pneumophila in the antigenuria era: the influence of levofloxacin therapy.
Clin Infect Dis, 40 (2005), pp. 794-799
[18.]
V.L. Yu, R.N. Greenberg, N. Zadeikis, J.E. Stout, M.M. Khashab, W.H. Olson, et al.
Levofloxacin efficacy in the treatment of community-acquired legionellosis.
Chest, 125 (2004), pp. 2135-2139
[19.]
J.F. Plouffe, R.F. Breiman, B.S. Fields, M. Herbert, J. Inverso, C. Kuirsch, et al.
Azithromycin in the treatment of Legionella pneumophila requiring hospitalization.
Clin Infect Dis, 37 (2003), pp. 1475-1480
[20.]
American Thoracic Society.
Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severtiy, antimicrobial therapy and prevention.
Am J Respir Crit Care Med, 163 (2001), pp. 1730-1754
[21.]
L.A. Mandell, J.G. Bartlett, S.F. Dowell, T.M. File Jr, D.M. Musher, C. Whituey, et al.
Update of fractice guidelines for the management of community-acquired pneumonia in immunocompetent adults.
Clin Infect Dis, 37 (2003), pp. 1405-1433
[22.]
B. Roson, J. Carratala, N. Fernández-Sabe, F. Tubau, F. Manresa, F. Gudiol.
Causes and factors associated with early failure in hospitalized patients wirth community-acquired pneumonia.
Arch Intern Med, 164 (2004), pp. 502-508
[23.]
A. Gacouin, Y. Le Tulzo, S. Lavoue, C. Camus, J. Hoff, R. Bassen, et al.
Severe pneumonia due to Legionella pneumophila: prognostic factors, impact of delayed appropriate antimicrobial therapy.
Intensive Care Med, 28 (2002), pp. 686-691
Copyright © 2006. Elsevier España S.L.. Todos los derechos reservados
